Syndax Pharmaceuticals Inc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $172.4M | $23.7M | $0 | $0 | $139.7M |
| Selling, general & administrative | $179.7M | $120.9M | $66.9M | $33.3M | $25.2M |
| Research and development | $258.8M | $241.6M | $163.0M | $118.5M | $88.2M |
| Operating expenses | $445.4M | $363.4M | $230.0M | $151.8M | $113.5M |
| Operating income | -$273.1M | -$339.7M | -$230.0M | -$151.8M | $26.2M |
| Interest expense | $6,000 | $1,000 | $208,000 | $3.1M | $1.9M |
| Income tax expense | $433,000 | — | — | — | $0 |
| Net income | -$285.4M | -$318.8M | -$209.4M | -$149.3M | $24.9M |
| Balance Sheet | |||||
| Cash and equivalents | $134.9M | $154.1M | $295.4M | $74.4M | $222.0M |
| Current assets | $528.1M | $603.1M | $580.9M | $489.8M | $448.4M |
| Total assets | $529.7M | $724.8M | $612.9M | $497.2M | $449.7M |
| Current liabilities | $120.1M | $103.5M | $58.1M | $29.1M | $20.7M |
| Total liabilities | $465.1M | $436.7M | $58.7M | $29.8M | $41.3M |
| Total debt | — | — | — | — | $20.0M |
| Stockholders' equity | $64.6M | $288.1M | $554.2M | $467.4M | $408.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$323.0M | -$274.9M | -$160.6M | -$133.7M | $29.1M |
| Depreciation and amortization | $6.0M | $8.0M | $12.0M | $33.0M | $43.0M |
| Stock-based compensation | $47.5M | $43.0M | $31.0M | $16.0M | $13.3M |
| Capital expenditure | $187,000 | $0 | $0 | $0 | $129,000 |
| Free cash flow | -$323.2M | -$274.9M | -$160.6M | -$133.7M | $29.0M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 88.6M · Free float 92.1%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.